ArticleEuropean journal of clinical pharmacology2022
Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018.
Article in European journal of clinical pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Proton pump inhibitor use: systematic review of global trends and practices.European journal of clinical pharmacology · 2023Pooled it
- Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method.British journal of clinical pharmacology · 2026Trial
- Efficacy of a computer based discontinuation strategy to reduce PPI prescriptions: a multicenter cluster-randomized controlled trial.Scientific reports · 2023Trial
- Factors associated with potentially inappropriate medication use, medication underuse and overuse in older adults in the German National Cohort.Journal of internal medicine · 2026Article
- Maternal PPI therapy during lactation: pantoprazole levels in human milk and possible neonatal implications.European journal of pediatrics · 2026Article
- Review
- Article
- Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients.Basic & clinical pharmacology & toxicology · 2025Article
- Factors associated with drug-drug interactions involving citalopram in the UK Biobank.BJPsych open · 2025Article
- Trends in Proton-Pump Inhibitor Use Among Danish Adults: A Nationwide Drug Utilization Study 2015-2023.Basic & clinical pharmacology & toxicology · 2025Article
- Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.The Journal of clinical endocrinology and metabolism · 2025Article
- Utilization of Acid Suppressants After Withdrawal of Ranitidine in Korea: An Interrupted Time Series Analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025Article
- Proton Pump Inhibitor Prescription in Nursing Home Residents: Prevalence, Appropriateness, and Associated Factors-A Secondary Data Analysis from Three German Regions and the Impact of Guideline Recommendations.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Gentamicin combination treatment is associated with lower mortality in patients with invasive listeriosis: a retrospective analysis.Infection · 2024Article
- Proton pump inhibitors in inpatients: Are we getting it right? A retrospective analysis.Qatar medical journal · 2024Article
- Proton Pump Inhibitors: Rational Use and Use-Reduction - The Windsor Workshop.Digestive diseases (Basel, Switzerland) · 2024Review
- Observational
- Missing PPI prescriptions while overprescribing?European journal of clinical pharmacology · 2023Article
- Time-Varying Use of Proton Pump Inhibitors and Cognitive Impairment and Dementia: A Real-World Analysis from Germany.Drugs & aging · 2023Article
- The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe German annual drug prescription-report has indicated overuse of proton pump inhibitors (PPIs) for many years; however, little was known about the characteristics of people using PPIs. This study aimed to provide comprehensive utilization data and describe frequencies of potential on- and off-label PPI-indications in Bavaria, Germany.
methodsClaims data of statutorily insured people from 2010 to 2018 were used. Defined daily doses (DDDs) of PPIs by type of drug, prevalence of PPI-use and DDDs prescribed per 1000 insured people/day were analyzed. For 2018, proportions of users and DDDs per 1000 insured people were calculated by age and sex. To elucidate changes in prescribing practices due to a suspected drug-drug interaction, we examined co-prescribing of clopidogrel and PPIs between 2010 and 2018. For PPI new users, sums of DDDs and frequencies of potential indications were examined.
resultsPPI prescribing increased linearly from 2010 to 2016 and gradually decreased from 2016 to 2018. In 2018, 14.7% of women and 12.2% of men received at least one prescription, and 64.8 DDDs (WHO-def.) per 1000 insured people/day were prescribed. Overall, omeprazole use decreased over the observation period and was steadily replaced by pantoprazole, especially when co-prescibed with clopidogrel. An on-label PPI-indication was not reported at first intake in 52.0% of new users.
conclusionsThe utilization of prescribed PPIs has decreased since 2016. However, a large proportion of new PPI-users had no documentation of a potential indication, and the sums of DDDs prescribed often seemed not to comply with guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.